A Randomised Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of GSK239512 in Stable Patients With Schizophrenia.

Trial Profile

A Randomised Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of GSK239512 in Stable Patients With Schizophrenia.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs GSK 239512 (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 18 Nov 2011 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
    • 18 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top